AveXis, Inc. (NASDAQ:AVXS) VP Sukumar Nagendran sold 1,780 shares of the stock in a transaction that occurred on Monday, October 2nd. The shares were sold at an average price of $97.25, for a total value of $173,105.00. Following the transaction, the vice president now directly owns 1,780 shares of the company’s stock, valued at approximately $173,105. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.

Sukumar Nagendran also recently made the following trade(s):

  • On Friday, September 1st, Sukumar Nagendran sold 1,780 shares of AveXis stock. The shares were sold at an average price of $93.25, for a total value of $165,985.00.
  • On Tuesday, August 1st, Sukumar Nagendran sold 1,780 shares of AveXis stock. The shares were sold at an average price of $91.52, for a total value of $162,905.60.

Shares of AveXis, Inc. (NASDAQ AVXS) traded up 3.67% during mid-day trading on Tuesday, reaching $99.27. The company’s stock had a trading volume of 623,475 shares. The firm’s market capitalization is $3.17 billion. The company’s 50-day moving average is $93.36 and its 200 day moving average is $82.25. AveXis, Inc. has a 1-year low of $41.89 and a 1-year high of $102.00.

AveXis (NASDAQ:AVXS) last released its quarterly earnings results on Thursday, August 10th. The company reported ($2.07) EPS for the quarter, missing the consensus estimate of ($0.97) by ($1.10). During the same quarter last year, the business posted ($0.68) EPS. On average, analysts expect that AveXis, Inc. will post ($6.04) earnings per share for the current year.

ILLEGAL ACTIVITY WARNING: “Sukumar Nagendran Sells 1,780 Shares of AveXis, Inc. (AVXS) Stock” was published by American Banking News and is the sole property of of American Banking News. If you are viewing this story on another publication, it was illegally stolen and reposted in violation of United States & international copyright & trademark laws. The legal version of this story can be accessed at https://www.americanbankingnews.com/2017/10/03/sukumar-nagendran-sells-1780-shares-of-avexis-inc-avxs-stock.html.

AVXS has been the topic of a number of research analyst reports. UBS AG reaffirmed a “buy” rating and issued a $122.00 price target (up from $95.00) on shares of AveXis in a research note on Tuesday. Citigroup Inc. boosted their price target on AveXis from $100.00 to $116.00 and gave the stock a “buy” rating in a research report on Monday. BMO Capital Markets reissued an “outperform” rating and issued a $123.00 price objective on shares of AveXis in a research note on Saturday. Wells Fargo & Company reissued an “outperform” rating on shares of AveXis in a research note on Friday. Finally, Royal Bank Of Canada initiated coverage on AveXis in a report on Thursday, September 14th. They issued a “sector perform” rating and a $92.00 price objective on the stock. Two investment analysts have rated the stock with a sell rating, three have given a hold rating and thirteen have given a buy rating to the company’s stock. AveXis currently has a consensus rating of “Buy” and a consensus price target of $101.82.

Hedge funds have recently bought and sold shares of the stock. BlackRock Inc. grew its holdings in AveXis by 3,055.6% during the 1st quarter. BlackRock Inc. now owns 1,708,386 shares of the company’s stock valued at $129,888,000 after buying an additional 1,654,248 shares during the last quarter. Janus Henderson Group PLC purchased a new position in AveXis during the second quarter worth $55,439,000. Alliancebernstein L.P. increased its position in AveXis by 4,448.8% during the second quarter. Alliancebernstein L.P. now owns 564,966 shares of the company’s stock worth $46,418,000 after buying an additional 552,546 shares in the last quarter. FMR LLC increased its position in AveXis by 13.1% during the second quarter. FMR LLC now owns 4,705,433 shares of the company’s stock worth $386,598,000 after buying an additional 544,475 shares in the last quarter. Finally, State Street Corp increased its position in AveXis by 104.2% during the second quarter. State Street Corp now owns 1,000,001 shares of the company’s stock worth $82,163,000 after buying an additional 510,189 shares in the last quarter. 94.71% of the stock is currently owned by hedge funds and other institutional investors.

About AveXis

AveXis, Inc is a clinical-stage gene therapy company. The Company operates through the developing and commercializing gene therapy treatments for patients suffering from neurological genetic diseases segment. The Company’s product candidate, AVXS-101, is its gene therapy product candidate that is in a Phase I clinical trial for the treatment of spinal muscular atrophy (SMA) Type 1, which is a genetic disorder characterized by motor neuron loss and associated muscle deterioration.

Receive News & Ratings for AveXis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AveXis Inc. and related companies with MarketBeat.com's FREE daily email newsletter.